29th Sep 2006 07:00
Hutchison China Meditech Limited29 September 2006 Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) Appointment of Senior Independent Director London, 29 September 2006: Chi-Med today announces that it has appointed Mr.Christopher Nash, an Independent Non-executive Director of Chi-Med since theadmission of trading of its shares on AIM in May this year, as its SeniorIndependent Director. Ends Enquiries Chi-Med Telephone: +852-2121-8200 Christian Hogg, CEO Citigate Dewe Rogerson Telephone: +44 (0) 20 7638 9571 Anthony Carlisle (07973 611 888) Chris Gardner (07903 737 649) Yvonne Alexander (07866 610 682) Notes to Editors Chi-Med is the holding company of a pharmaceutical and healthcare group basedprimarily in China and was admitted to trading on the Alternative InvestmentMarket of the London Stock Exchange in May 2006. Chi-Med is focused onresearching, developing, manufacturing, and selling pharmaceuticals, healthsupplements and other consumer health and personal care products derived fromTraditional Chinese Medicine and botanical ingredients. Its overall aim is todraw on the untapped wealth of knowledge and history of usage in the TraditionalChinese Medicine industry to develop products for the global market. The Companyhas three complementary businesses: drug R&D, China healthcare and consumerproducts. Chi-Med is majority owned by Hutchison Whampoa Limited, an internationalcorporation listed on the Main Board of The Stock Exchange of Hong Kong Limited. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hutchmed